Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,315 shares of the medical equipment provider’s stock after selling 545 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Lantheus were worth $1,728,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new position in Lantheus in the third quarter worth approximately $25,000. Kestra Investment Management LLC acquired a new position in Lantheus in the fourth quarter worth approximately $27,000. UMB Bank n.a. grew its position in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares in the last quarter. RiverPark Advisors LLC purchased a new position in Lantheus during the 3rd quarter worth approximately $74,000. Finally, Farther Finance Advisors LLC grew its position in Lantheus by 226.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 526 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 6.1 %

Lantheus stock opened at $106.34 on Friday. The company’s fifty day simple moving average is $90.43 and its 200-day simple moving average is $96.80. Lantheus Holdings, Inc. has a 12 month low of $56.44 and a 12 month high of $126.89. The stock has a market cap of $7.28 billion, a P/E ratio of 17.69 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

LNTH has been the topic of several research analyst reports. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.